Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy | 1 | Investing.com | ||
Fr | Praxis Precision Medicines: FDA erteilt Relutrigin Breakthrough-Therapy-Status - H.C. Wainwright bestätigt Kaufempfehlung | 1 | Investing.com Deutsch | ||
Do | Praxis Precision gets FDA breakthrough therapy status for Relutrigine | 3 | Seeking Alpha | ||
Do | Praxis Precision Medicines: FDA verleiht Epilepsie-Wirkstoff Relutrigin den Status einer bahnbrechenden Therapie | 4 | Investing.com Deutsch | ||
Do | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | 86 | GlobeNewswire (Europe) | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
Do | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.07. | Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock | 2 | Investing.com | ||
10.07. | Piper Sandler bestätigt "Overweight" für Praxis Precision Medicines und sieht hohes Kurspotenzial | 2 | Investing.com Deutsch | ||
PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
02.07. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 79 | GlobeNewswire (Europe) | BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
27.06. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.06. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 136 | GlobeNewswire (Europe) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
02.06. | Oppenheimer assigns outperform rating to Praxis Precision Medicines stock | 2 | Investing.com | ||
07.05. | Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside | 1 | Benzinga.com | ||
02.05. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 240 | GlobeNewswire (Europe) | BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
02.05. | Praxis Precision Medicines GAAP EPS of -$3.29 | 1 | Seeking Alpha | ||
02.05. | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
02.05. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results | 271 | GlobeNewswire (Europe) | On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025:... ► Artikel lesen | |
02.05. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies | 1 | GlobeNewswire (USA) | ||
08.04. | Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) | 1 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,456 | +0,59 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
MODERNA | 27,305 | -2,45 % | Tesla und Moderna: Das sind die Short-Kandidaten von JPMorgan | © Foto: DALL*ETesla und Moderna gehören zu den Aktien, bei denen JPMorgan im zweiten Halbjahr 2025 zu Short-Positionen rät.Zum Start ins zweite Halbjahr ließ Pedro Martins Junior, Co-Leiter der US-Aktienanalyse... ► Artikel lesen | |
AMGEN | 253,90 | +0,10 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
NOVAVAX | 6,025 | -0,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BIOGEN | 107,50 | -0,09 % | Here's What to Expect From Biogen's Next Earnings Report | ||
ILLUMINA | 82,73 | 0,00 % | Illumina Stock: What Went Wrong And Why It's Best To Stay Away | ||
CRISPR THERAPEUTICS | 56,00 | 0,00 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
INOVIO PHARMACEUTICALS | 1,230 | +1,65 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
OCUGEN | 0,860 | -1,53 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 10,295 | -0,82 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
COSCIENS BIOPHARMA | 3,360 | +7,01 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
EDITAS MEDICINE | 2,360 | -0,46 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,316 | -1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development | RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 12,080 | -0,29 % | Aktien New York: Weitere Gewinne nach guten Firmennachrichten | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Donnerstag an ihre freundliche Vortagsentwicklung angeknüpft. Der Leitindex Dow Jones Industrial notierte zuletzt 0,44 Prozent höher bei 44.447,68... ► Artikel lesen |